Biopharmaceutical company Akeso Inc (HKEX:9926) announced on Wednesday that a pre-specified interim analysis in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Data Monitoring Committee, met the key secondary endpoint of overall survival.
According to the company, the results demonstrated that ivonescimab showed statistically significant and clinically meaningful improvement over pembrolizumab.
HARMONi-2 is a randomised, double-blind, multicentre, registrational Phase III trial evaluating ivonescimab, Akeso's first-in-class PD-1/VEGF bispecific antibody, versus pembrolizumab as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours express PD-L1 (TPS greater than 1%).
Detailed data from the interim analysis of overall survival will be presented at an upcoming international medical conference and published in a peer-reviewed journal.
Daiichi Sankyo and AstraZeneca launch phase 3 trial of Datroway in high-risk bladder cancer
Inify Laboratories launches UK operations with first NHS agreement
Senhwa completes enrolment in Phase 1b expansion trial of CX-5461
McKesson to acquire Precision Medicine Group for approximately USD2.25bn
Astellas doses first patient in Phase 3 study of ASP2138
Gilead expands Trodelvy role in first-line metastatic triple-negative breast cancer in Europe
GSK's Jemperli wins FDA priority review for advanced rectal cancer
Leads Biolabs NDA for Opamtistomig accepted by China's CDE
Ipsen completes Kartos Therapeutics acquisition, strengthening late-stage oncology pipeline
Nuvation Bio's safusidenib granted FDA Fast Track Designation for IDH1-mutant glioma treatment
Maverix Medical's Narwhal Cryo System receives FDA 510(k) clearance
Annexin Pharmaceuticals receives proposed INN vanexin for ANXV